Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Nutrien Ltd. Stock Rises Wednesday, Outperforms Market

Nutrien Ltd. Stock Rises Wednesday, Outperforms Market

Dow JonesDow Jones2026/08/26 20:34

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of Nutrien Ltd. NTR rose 1.49% to C$102.18 Wednesday, in what proved to be an otherwise all-around negative trading session for the Canadian market, with the S&P/TSX Composite Index falling 0.39% to 36,813.65.

Nutrien Ltd. closed 12.6% below its 52-week high of C$116.95, which the company achieved on March 13th.

Trading volume of 791,348 shares remained below its 50-day average volume of 1.6 M.

Data source: Dow Jones Market Data, FactSet. Data compiled August 26, 2026.

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

August 26, 2026 16:34 ET (20:34 GMT)

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Why did the Reserve Bank of Australia raise interest rates two weeks ago? Meeting minutes reveal inflation risks have become a reality, and waiting would be too costly

The Reserve Bank of Australia acknowledges that the trade-off between inflation and full employment has worsened, but maintains that its goal is to return the Consumer Price Index (CPI) to the 2-3% target range.

智通财经•2026/10/13 02:41

Three-year remission rate up to 94%! Johnson & Johnson (JNJ.US) Tremfya Crohn's disease study shows positive long-term results

Long-term data from two Phase 3 clinical trials by Johnson & Johnson show that adult Crohn's disease patients treated with Tremfya (guselkumab) achieved a clinical remission rate of up to 94% over three years.

智通财经•2026/10/13 01:56